Improvements in patients’ quality of life following treatment with intravesical hyaluronic acid (Cystistat 40 mg) for bladder pain syndrome and recurrent UTIs

Abstract

Introduction:

Intravesical hyaluronic acid (Cystistat) is indicated for a variety of chronic cystitis conditions including bladder pain syndrome, recurrent bacterial urinary tract infections and radiation or chemical cystitis. Previously published studies have predominantly assessed the outcome in terms of bladder symptoms (frequency/urgency/nocturia/pain) or in the case of recurrent bacterial urinary tract infection, by microbiological response. The aim of this study was to assess improvement in patients’ quality of life following treatment with intravesical Cystistat.

Materials and methods:

Patients’ referred for treatment with intravesical Cystistat for either bladder pain syndrome or recurrent bacterial urinary tract infection completed the King’s health questionnaire. Patients were treated with a 6-week course of Cystistat by one of two specialist urology nurses. If treatment was effective further instillations were given every 2–4 weeks for up to 6 months. King’s health questionnaire scores were repeated after 6 weeks and 6 months and were analysed.

Results:

Twenty patients (18 women, 2 men) were included: 8 bladder pain syndrome, 12 recurrent bacterial urinary tract infections. There were four treatment failures within 6 weeks, of whom three were being treated for recurrent bacterial urinary tract infections. Of the 16 patients who continued with treatment beyond 6 weeks, 12 have 6-month scores available. The average initial King’s health questionnaire score was 500.8 (534.1 for the recurrent bacterial urinary tract infection group, 450.8 for the bladder pain syndrome group). After six treatments average King’s health questionnaire scores improved to 426.3 (457.7 for recurrent bacterial urinary tract infections, 372.4 for bladder pain syndrome). After 6 months, average scores significantly improved to 278 overall (303.2 (P<0.05) for the recurrent bacterial urinary tract infections group, 252.8 (P>0.05) for the bladder pain syndrome group).

Conclusion:

Intravesical Cystistat should be considered in all patients with bladder pain syndrome and recurrent bacterial urinary tract infections. We have shown a significant, clinically important, improvement in patients’ quality of life in refractory bladder pain syndrome and recurrent bacterial urinary tract infections. In future Cystistat could be considered as an alternative to long-term low-dose antibiotic prophylaxis.

Level of evidence:

Keywords

Bladder pain syndrome recurrent urinary tract infection hyaluronic acid quality of life

Get full access to this article

View all access options for this article.

References

Raymond

Vasdev

Ferguson

, et al. The clinical effectiveness of intravesical sodium hyaluronate (Cystistat®) in patients with interstitial cystitis/painful bladder syndrome and recurrent urinary tract infections. Curr Urol 2012; 6(2): 93–8.

Payne

Adamson

Bahl

, et al. Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int 2013; 112(7): 885–97.

Thompson

Adamson

Bahl

, et al. Guidelines for the diagnosis, prevention and management of chemical- and radiation-induced cystitis. J Clin Urol 2014; 7(1): 25–35.

Doggweiler

Whitmore

Meijlink

, et al. A standard for terminology in chronic pelvic pain syndromes: a report from the chronic pelvic pain working group of the international continence society. Neurourol Urodyn 2017; 36(4): 984–1008.

Iavazzo

Athanasiou

Pitsouni

, et al. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007; 51(6): 1534–40.

Lazzeri

Montorsi

The therapeutic challenge of “chronic cystitis”: search well, work together, and gain results. Eur Urol 2011; 60(1): 78–80.

Parsons

CL.

Bladder surface glycosaminoglycan: efficient mechanism of environmental adaptation. Urology 1986; 27(2 Suppl): 9–14.

Lazzeri

Hurle

Casale

, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Therapeut Adv Urol 2016; 8(2): 91–99.

Bokat

Pickard

Bartoletti

, et al. EAU Guidelines on urological infections. Eur Assoc Urol 2018.

10.

Hanno

Lin

Nordling

, et al. Bladder pain syndrome international consultation on incontinence. Neurourol Urodynam 2010; 29(1): 191–8.

11.

Okamura

Nojiri

Osuga

Reliability and validity of the King’s Health Questionnaire for lower urinary tract symptoms in both genders. BJU Int 2009; 103(12): 1673–8.

12.

Kelleher

Pleil

Reese

, et al. How much is enough and who says so? BJOG 2004; 111(6): 605–12.

13.

Barua

Arance

Angulo

, et al. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. Int Urogynecol J 2016; 27(8): 1137–47.

14.

Cocci

Alowidah

Skews

, et al. 421 Comparison of Cystistat®, iAluril®, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis. Eur Urol Suppl 2016; 15(3): e421.

15.

Ciani

Arendsen

Romancik

, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open 2016; 6(3): e009669.